- Previous Close
15.87 - Open
15.90 - Bid --
- Ask --
- Day's Range
15.50 - 16.14 - 52 Week Range
14.30 - 34.70 - Volume
57,343 - Avg. Volume
236,496 - Market Cap (intraday)
867.18M - Beta (5Y Monthly) -0.11
- PE Ratio (TTM)
1.57 - EPS (TTM)
10.14 - Earnings Date Feb 12, 2025 - Feb 17, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 21, 2011
- 1y Target Est
--
Ind-Swift Limited develops pharmaceutical formulations, finished goods dosages, active pharmaceutical ingredients, and herbal products in India. The company offers medicines for various therapeutic segments, such as ENT, dentistry, anti-infective, cardio-diabetic, and orthopedic therapies under the Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin, and Stemin Forte names. It also offers medicines for various therapeutic comprising gynaecology, pediatrics, dermatology, and other generic medicines under the Anin, Suprox, Cozy, Distone, and Oliade name. In addition, the company provides antibiotic, anti-cold, nutraceuticals, anti-diarrhoeal, anti-malarial, anti-depressants, cardiology, diabetology, anti-depressant, anti-allergic, anti- infective, neurology, and oncology. Ind-Swift Limited provides Ayurvedic products, as well as contract research and manufacturing services. The company exports its products, as well as licenses its products to Europe, Australia, Canada, South Africa, and Russia. Swift Limited was founded in 1983 and is based in Chandigarh, India.
www.indswiftltd.com1,054
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: INDSWFTLTD.NS
View MorePerformance Overview: INDSWFTLTD.NS
Trailing total returns as of 2/7/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: INDSWFTLTD.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: INDSWFTLTD.NS
View MoreValuation Measures
Market Cap
866.63M
Enterprise Value
10.41B
Trailing P/E
1.57
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.18
Price/Book (mrq)
--
Enterprise Value/Revenue
2.18
Enterprise Value/EBITDA
8.08
Financial Highlights
Profitability and Income Statement
Profit Margin
8.58%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
4.68B
Net Income Avi to Common (ttm)
401.08M
Diluted EPS (ttm)
10.14
Balance Sheet and Cash Flow
Total Cash (mrq)
631.37M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--